Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644485 | PMC |
http://dx.doi.org/10.2169/internalmedicine.4992-20 | DOI Listing |
J Affect Disord
January 2025
Affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu 214151, China. Electronic address:
Objective: This study aims to analyze the distribution of adverse events (AEs) related to Lecanemab in real-world settings based on FAERS database data.
Methods: Using the FAERS database, AE data related to Lecanemab was collected from Q3 2023 to Q2 2024. Signal mining was conducted using frequency and Bayesian methods to identify positive signals associated with Lecanemab.
J Neuropathol Exp Neurol
December 2024
Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, United States.
Microinfarcts and microhemorrhages are characteristic lesions of cerebrovascular disease. Although multiple studies have been published, there is no one universal standard criteria for the neuropathological assessment of cerebrovascular disease. In this study, we propose a novel application of machine learning in the automated screening of microinfarcts and microhemorrhages.
View Article and Find Full Text PDFBiomed Pharmacother
January 2025
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address:
The technology of focused ultrasound-mediated disruption of the blood-brain barrier (FUS-BBB opening) has now been used in over 20 Phase 1 clinical trials to validate the safety and feasibility of BBB opening for drug delivery in patients with brain tumors and neurodegenerative diseases. The primary treatment parameters, FUS intensity and microbubble dose, are chosen to balance sufficient BBB disruption to achieve drug delivery against potential acute vessel damage leading to microhemorrhage. However, other safety considerations due to second order effects caused by BBB disruption, such as inflammation and alteration of neurovascular function, are only beginning to be understood.
View Article and Find Full Text PDFNeural Regen Res
December 2024
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao Special Administrative Region, China.
Drug development for Alzheimer's disease Is extremely challenging, as demonstrated by the repeated failures of amyloid-β-targeted therapeutics and the controversies surrounding the amyloid-β cascade hypothesis. More recently, advances in the development of Lecanemab, an anti-amyloid-β monoclonal antibody, have shown positive results in reducing brain A burden and slowing cognitive decline in patients with early- stage Alzheimer's disease in the Phase III clinical trial (Clarity Alzheimer's disease). Despite these promising results, side effects such as amyloid-related imaging abnormalities (ARIA) may limit its usage.
View Article and Find Full Text PDFVet Radiol Ultrasound
January 2025
IVC Evidensia GmbH, Hofheim Animal Hospital, Hofheim am Taunus, Germany.
A 2-year-old intact male Airedale Terrier was presented with a sudden onset of neurological signs, manifesting as hemiparesis, which were neuroanatomically localized to the brain. Initial bloodwork conducted by the local veterinarian indicated decreased levels of von Willebrand factor, and further examination showed an extended buccal mucosal bleeding time. MRI revealed a substantial hemorrhage within the right parietal lobe, while CT exhibited a mixed pulmonary pattern with unstructured interstitial, peribronchial, and alveolar components, presumably associated with larval migration and pulmonary microhemorrhages.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!